Experts to weigh in on Amgen's Nplate

Amgen is going before the FDA's Oncologic Drugs Advisory Committee (ODAC) in order to discuss its BLA for Nplate (romiplostim). The drug is a treatment for thrombocytopenia, a disorder that causes the body to attack its own blood clotting cells. The FDA is concerned about adverse reactions noted in clinical trials. These include significantly higher platelet levels, dangerous blood clots, bone marrow growth and malignant tumors in those taking the drug. The experts will advise the FDA whether Nplate's benefits outweigh the risks, and whether it should be given a limited approval.

- check out this release
- and read the AP article for more

ALSO: Here's a peek into the FDA playbook for tomorrow's advisory panel on Amgen and Johnson & Johnson's anemia drugs. According to documents posted on the agency's website, those expert advisors will be asked to consider several limitations on the meds, which have been linked to increased tumor growth and reduced survival among some cancer patients. And the options include yanking FDA approval for that use. Report

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.